Is Ruxolitinib cream effective?

The pathophysiology of atopic dermatitis includes skin barrier dysfunction, acute and chronic inflammation, and pruritus. In multiple preclinical models of dermatitis, topical application of Ruxolitinib cream significantly improved pathogenic itching and skin inflammation. These clinical data strengthen the scientific rationale for topical JAK-STAT pathway inhibition treatment of atopic dermatitis. Ruxolitinib cream has been shown to have beneficial effects on skin pigmentation in patients with non-segmental vitiligo. From a safety perspective, the side effects of ruxolitinib cream are considered acceptable, provided that no more than 10% of the body's total dose is used at one time.